Ashwani Verma
Stock Analyst at UBS
(3.34)
# 995
Out of 4,711 analysts
55
Total ratings
51.28%
Success rate
3.45%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Maintains: Buy | $106 → $114 | $75.54 | +50.91% | 2 | Dec 10, 2024 | |
| EXEL Exelixis | Initiates: Neutral | $30 | $33.29 | -9.88% | 1 | Sep 19, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $56 | $34.28 | +63.36% | 1 | Sep 10, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $24 → $26 | $22.09 | +17.70% | 6 | Sep 3, 2024 | |
| CHRS Coherus BioSciences | Downgrades: Neutral | $4 → $1.5 | $1.52 | -1.32% | 4 | Aug 16, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $54 | $36.26 | +48.92% | 3 | Aug 13, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $83 → $79 | $83.45 | -5.33% | 5 | Aug 8, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $23 | $16.87 | +36.34% | 3 | Aug 8, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $107 → $105 | $90.73 | +15.73% | 2 | Aug 6, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $300 → $370 | $359.58 | +2.90% | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $117 → $113 | $122.97 | -8.11% | 5 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $24.92 | +12.36% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $174 → $193 | $135.42 | +42.52% | 4 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $34.08 | +137.68% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $25 | $29.71 | -15.85% | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $10.31 | +103.69% | 1 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $61 → $92 | $48.87 | +88.25% | 4 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $97.67 | -92.83% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $12.52 | -4.15% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.40 | +971.43% | 1 | Oct 11, 2022 |
Arcellx
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $75.54
Upside: +50.91%
Exelixis
Sep 19, 2024
Initiates: Neutral
Price Target: $30
Current: $33.29
Upside: -9.88%
Harmony Biosciences Holdings
Sep 10, 2024
Initiates: Buy
Price Target: $56
Current: $34.28
Upside: +63.36%
Teva Pharmaceutical
Sep 3, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.09
Upside: +17.70%
Coherus BioSciences
Aug 16, 2024
Downgrades: Neutral
Price Target: $4 → $1.5
Current: $1.52
Upside: -1.32%
Biohaven
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $36.26
Upside: +48.92%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $83 → $79
Current: $83.45
Upside: -5.33%
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $16.87
Upside: +36.34%
Axsome Therapeutics
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $90.73
Upside: +15.73%
United Therapeutics
Jul 8, 2024
Maintains: Buy
Price Target: $300 → $370
Current: $359.58
Upside: +2.90%
Jul 2, 2024
Maintains: Neutral
Price Target: $117 → $113
Current: $122.97
Upside: -8.11%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $24.92
Upside: +12.36%
May 28, 2024
Maintains: Buy
Price Target: $174 → $193
Current: $135.42
Upside: +42.52%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $34.08
Upside: +137.68%
Feb 20, 2024
Downgrades: Sell
Price Target: $25
Current: $29.71
Upside: -15.85%
Feb 6, 2024
Initiates: Buy
Price Target: $21
Current: $10.31
Upside: +103.69%
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $48.87
Upside: +88.25%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $97.67
Upside: -92.83%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $12.52
Upside: -4.15%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.40
Upside: +971.43%